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Abstract
Introduction: The purpose of our study was to examine the efficacy and safety of intravenous chemotherapy during intensive 
treatment phase in patients with newly diagnosed pulmonary tuberculosis (pulmonary TB).
Material and methods: The study involved 92 patients with newly diagnosed pulmonary TB aged between 20 and 68. All patients 
with newly diagnosed pulmonary TB and chemosensitive tuberculosis were enrolled in the study. The patients were allocated to 
two groups. The first (control) group of 46 patients received standard chemotherapy orally. The second (main) group consisted of 
46 patients who were prescribed isoniazid, rifampin, ethambutol by i.v. infusion, and pyrazinamide orally as a part of the standard 
treatment.
Results: Symptoms of intoxication and chest manifestations in pulmonary TB patients from the second group were eliminated faster than 
the same symptoms in the group 1. In the group 2, the mycobacterial clearance in sputum smears was achieved more rapidly, and up to 
2 months it was reached in 37 patients (80.43%), while in the control group in 25 patients (54.35%),p = 0.0066. Destruction 
healing and inflitrative change alleviation after 4 months was reached in 38 patients (82.61%) (in control group — 28 (60.87%), 
(p = 0.0192). No additional negative effects were detected when compared with the control group at any time.
Conclusions: Thanks to i.v. chemotherapy, clinical manifestations of the in-patients with pulmonary TB were eliminated faster, 
severe side effects of anti-TB drugs were not noticed, time of bacterial clearance and healing of destruction was shorter, healing 
frequency of destructions increased and the of residual changes decreased.
Key words: tuberculosis, treatment of tuberculosis, intravenous treatment of tuberculosis, antituberculous drugs
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Introduction
Tuberculosis (TB) continues to hold a domi-
nant position among frequent infections, consti-
tuting a threat to the population of most countries, 
including the economically developed ones [1]. 
TB problem is extremely important in Ukraine, 
where since 1995 it has been registered an epi-
demic, and although the growth rate of morbidity 
and mortality from TB has been stabilized in 
recent years, the situation still remains difficult. 
Despite the reduction in the growth of total inci-
dence rate, prevalence and mortality from TB for 
the last 5 years remain high and exceed 2–3 times 
the epidemic threshold [1, 2].
The most prominent achievements of phthisi-
ology are associated with the development of 
antimycobacterial therapy. Performance targets 
for further improvement of the newly diagnosed 
pulmonary TB treatment determine not only the 
increasing of destructions closure frequency and 
negation of sputum, but also the use of therapies 
Advances in Respiratory Medicine 2018, vol. 86, no. 4, pages 159–167 
160 www.journals.viamedica.pl
that can achieve sustainable results within short-
er time without forming large residual changes in 
the lungs [3–5].
Modern methods of controlled therapy rep-
resent programmable treatment [6]. Foreign and 
domestic experience of DOTS program implemen-
tation has shown that treatment standardization 
and control procedures of its effectiveness are not 
always justified [7, 8]. The success of the used 
therapy depends with great frequency on the 
possibility to apply a full course of chemotherapy, 
namely the administration of the required num-
ber of drugs in adequate doses for the necessary 
duration of treatment [9, 10].
However, there remains a certain percentage 
of patients for whom this method of treatment 
does not lead to significant improvement of he-
alth. This generalized treatment method does not 
consider the presence of comorbidities and deve-
lopment of side effects of therapy, which require 
treatment correction [11]. Despite the high level 
of scientific and practical justification of existing 
standards of TB chemotherapy, its further impro-
vement is necessary [12, 13].
The lack of therapeutic effect may be caused 
by the development of drug resistance [14], the 
inability to create optimal concentrations of the 
drugs in the blood and tissues [15] as a result of 
their incomplete absorption in the gastrointesti-
nal tract [16] and accumulation in the inflam-
mation area [4, 17], or rapid inactivation of the 
drugs [18].
In the course of clinical and experimental 
studies it was found that the therapeutic effect 
of ATD (anti- TB drugs) is directly related to the 
concentration of a drug in the blood, and there-
fore to the area of specific inflammation [19, 20]. 
According to the literature, there are some data 
about the use of intravenous (i.v.) chemotherapy 
in patients with TB meningitis. Those figures 
show that this type of intensive treatment reduces 
mortality of patients with TB meningitis [21]. In 
addition, effectiveness of i.v. chemotherapy for 
patients with TB and deficit of absorption have 
been also shown [22].
All this determines the search for ways to 
improve the treatment of patients with newly 
diagnosed pulmonary TB by optimization of the 
intensive phase of TB chemotherapy with i.v. 
use of ATD.
Thus, the purpose of our research was to 
study the effectiveness and safety of intravenous 
chemotherapy in the intensive phase of treatment 
of patients with newly diagnosed pulmonary TB 
(pulmonary TB).
Material and methods
Patients
This prospective, randomized, comparative 
study was conducted in SO “National Institute of 
phthisiology and pulmonology named after F. G. 
Yanovskyi NAMS of Ukraine”, Kyiv and Kharkiv 
National Medical University, Kharkiv, Ukraine.
The study involved 92 patients with pulmo-
nary TB aged between 20 and 68 . The period of 
inclusion of patients in the study was from 2011 
to 2017. All patients with pulmonary TB and 
chemosensitive TB were enrolled in the study. 
Patients were randomly allocated by computer-
generated sequence into two groups. The first 
(control) group of 46 subjects received standard 
chemotherapy orally. The second (main) group 
consisted of 46 patients who were prescribed iso-
niazid, rifampin, ethambutol in standard dose by 
i.v. infusion, as a part of the standard treatment.
The randomization resulted in equal dis-
tribution of baseline characteristics: age, gen-
der, height, body weight, comorbidities, serum 
biochemistry parameters, severity and various 
manifestations of the disease (Tables 1–3).
Active pulmonary TB was defined by a med-
ical history and clinical findings compatible with 
TB, a  chest X-ray showing lung involvement, 
and a positive sputum smear for acid-fast bacilli 
and positive culture for MTB. On the patients’ 
admission to hospital, infiltrative pulmonary TB 
was the most common type and was observed in 
every patient from the first group. In the second 
group, infiltrative pulmonary TB was observed 
in 43 (93.48%) patients. Moreover, 3 (6.52%) in-
dividuals from the second group were diagnosed 
with disseminated pulmonary TB. Quantitative 
characteristics of TB cases within both groups of 
patients were evaluated and shown to be insignifi-
cant (p > 0.05). The difference between the spread 
of the TB process in the lungs and the number and 
size of destructions was insignificant (p > 0.05).
Treatment regimen
All patients from the first group received 
standard chemotherapy, consisting of orally 
administered isoniazid (0.3 g), rifampin (0.6 g), 
pyrazinamide (2 g), ethambutol (1.2 g) with 
a dose reduction after the intensive phase of the 
therapy. The ATD were procured through the 
Ukraine’s centralized national supply system. 
The second group was treated with i.v. che-
motherapy, i.e. isoniazid (used in a dose of 100 
mg/ml in 5 ml of i.v. (intravenous jet, slowly) — by 
stream infusion once per day for 60 days starting 
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on admission to the hospital), rifampin (used 
in a dose of 600 mg in 20 ml of 0.9% in 200 ml 
sodium chloride solution i.v. (intravenous drips, 
slowly) — by drop infusion once per day for 60 
days starting on admission to the hospital), eth-
ambutol (used in a dose of 100 mg/ml in 20 ml of 
5% in 200 ml glucose solution i.v. (intravenous 
drips, slowly) — by drop infusion once per day 
for 60 days starting on admission to the hospital) 
and pyrazinamide (2 g in tablets orally). Intrave-
nous administration of the ATD was performed 
in the ulnar vein. Parenteral chemotherapy was 
performed in the 2nd group only during the inten-
sive phase of treatment (60 doses), and during 
the continuation phase ATD were taken orally in 
a standard dosage.
Laboratory evaluation
A standard microbiological examination of 
a stained sputum smear using the Ziehl-Neelsen 
and culture Lowenstein-Jensen methods was con-
ducted prior to study entry and on the 30th, 60th, 
90th, and 150th day from the start of the treatment. 
Isolates of MTB were tested for sensitivity to 
first- and second-line anti-TB drugs with a com-
mercially available kit (Tulip Diagnostics Pvt Ltd., 
Goa, India). The biochemical parameters were 
evaluated using standard routine techniques at 
baseline and repeated 2 months later.
Bacteriostatic blood activity (BBA) was iden-
tified in TB patients against the standard labo-
ratory strain of the Mycobacterium tuberculosis 
(MBT) H37Rv on the liquid Proskauer-Beck 
medium using the procedure of Rudoy VV [23]. 
The elements of test-strain film were placed into 
test-tube and incubated in the thermostat during 
10 days. At the presence of growth in the control 
sample, which covered its entire surface, the 
results were counted. The level of BBA was es-
timated according to the greatest blood dilution, 
where the MBT growth inhibition was observed. 
The BBA level was considered low in dilutions 
of 1: 2–1:4; average 1: 8–1:16; high 1:32–1:512. 
All patients admitted to the hospital were 
tested for HIV with the use of rapid tests. All 
subjects were HIV-negative.
X-ray evaluation
Pathological peculiarities, for example, the 
severity of the disease and changes in localiza-
tion, were assessed through X-ray. Chest fluo-
rography was performed in the outpatient de-
partment for every subject involved in the study. 
In cases of pathological findings, we conducted 
a chest X-ray (two views). Targeted tomography 
of the destructed area on selected sections was 
performed in every patient. Interpretation of 
the thorough X-ray examination allowed us to 
estimate the first TB diagnosis, specifically, to 
detect localization, severity, and peculiarities of 
TB destructions in the lungs.
X-ray monitoring of patients was repeated ev-
ery 2 months following the start of treatment until 
the end of the continuation phase (6 months). 
Statistical evaluation 
The obtained data were statistically analyzed 
using standard Student t test [24]. The difference 
was considered to be significant at p < 0.05.
Ethics approval and consent to participate
The project was approved by the Ethics Com-
mittee of the SO “National Institute of phthisiolo-
gy and pulmonology named after F. G. Yanovskyi 
NAMS of Ukraine”, Kyiv, Ukraine. It was conduct-
ed according to the Declaration of Helsinki stan-
dards. All of the patients gave written informed 
consent and explicitly provided permission for 
treatment and blood analyses, as well as for the 
collection of relevant clinical data.
Results
This study comprised 92 TB patients. The 
baseline characteristics of patients in the two 
treatment groups were not statistically different, 
indicating that the outcome was not biased by 
sample heterogeneity (Tables 1–3).
Regression of intoxication and chest symp-
toms were the hallmarks of estimating how 
rapidly disease manifestation terminates after 
i.v. chemotherapy administration. Chest symp-
toms were evaluated through dyspnea, cough, and 
chest pain reduction or alleviation. Intoxication 
symptom regression was evaluated regarding 
subjective symptoms (increased appetite, gen-
eral revival, fatigue, and sweating alleviation), 
normalization of body temperature, and body 
weight, which were considered symptoms of TB 
intoxication. Data are shown in Table 2. There-
fore, in the second group, patients demonstrated 
more rapid intoxication and chest symptom al-
leviation than in the first group. Fever is mainly 
related to the severity of the specific process in 
the lungs lesions. They attenuated more rapidly in 
patients of the second group in comparison with 
the first group, which is explained by the high 
detoxication effect of i.v. chemotherapy during 
the treatment. This can be accounted for a low 
number of side effects of the therapy among the 
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Table 1. Baseline characteristics of patients with pulmonary TB
Characteristics Group 1
n = 46
Group 2
n = 46
p-value
Age 42.06 ± 1.20 40.78 ± 1.24 0.4621
Males 36 (78.26%) 32 (69.57%) 0.3425
Females 10 (21.74%) 14 (30.43%) 0.3425
Height, cm 166.2 ± 1.55 162.9 ± 1.52 0.1371
Weight, kg 55.09 ± 1.29 55.78 ± 0.99 0.6710
Co-morbidities*:
Diseases of the respiratory system 13 (28.26%) 11 (23.91%) 0.6355
Diseases of the cardiovascular system 19 (41.30%) 21 (45.65%) 0.6745
Diseases of the gastrointestinal tract 7 (15.22%) 9 (19.57%) 0.5829
Diseases of the central nervous system 4 (8.70%) 7 (15.22%) 0.3353
Disease of the urogenital system 2 (4.35%) 3 (6.52%) 0.6469
Rheumatic diseases 2 (4.35%) 2 (4.35%) 1.000
Diabetes 7 (15.22%) 9 (19.57%) 0.5829
Psoriasis 2 (4.35%) 1 (2.17%) 0.5570
Chronic alcoholism 8 (17.39%) 9 (19.57%) 0.7882
*in many patients, concomitant diseases were combined
Table 2. Period of reduction of tuberculosis clinical signs in patients of the groups
Clinical symptoms Group 1 Group 2
No. at the 
beginning of 
treatment 
Terms of 
disappearance 
of clinical signs 
(months)
No. at the 
beginning
of treatment p-value#
Terms of 
disappearance 
of clinical signs 
(months)
p-value* 
n % n %
Intoxication symptoms:
Weakness 28 60.87 2.77 ± 0.59 33 71.74 0.2700 1.22 ± 0.36 0.0238
Loss of appetite 10 21.74 2.49 ± 0.75 13 28.26 0.4708 0.87 ± 0.21 0.0298
Fatigue 13 28.26 3.67 ± 0.39 15 32.61 0.6508 2.06 ± 0.41 0.0088
Night sweats 22 47.83 3.41 ± 0.69 25 54.35 0.5323 1.08 ± 0.48 0.0070
Increased body temperature 26 56.52 2.68 ± 1,01 30 65.22 0.3929 0.61 ± 0.39 0.0490
Chest symptoms:
Cough 36 78.26 4.89 ± 0.71 38 82.61 0.5987 2.14 ± 0.77 0.0107
Dyspnea 24 52.17 1.89 ± 0.53 27 58.70 0.5294 0.51 ± 0.30 0.0235
Pain in the chest 4 8.70 3.57 ± 0.49 5 13.04 0.5043 1.38 ± 0.51 0.0189
*the p-value is the significance of difference between parameters in Groups 1 and 2 (No. at the beginning of treatment); # the p-value is not the significance of diffe-
rence between parameters in Groups 1 and 2 (Terms of disappearance of clinical signs)
observed patients of the 2nd group, which is asso-
ciated with the slow administration of rifampin 
and ethambutol in a reasonably large amount of 
solution (400 ml) per day. 
When studying the basic biochemical indica-
tors during the treatment (Table 3), we did not find 
significant changes in the concentration of total 
bilirubin and protein — these indicators were 
within normal range either before the treatment 
or after two months except for the rare cases. 
However, special attention should be paid to in-
dicators such as alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) concentra-
tions. As shown in Table 3, the TB toxicity in the 
organisms of patients of the group 2 prior to treat-
ment was higher compared to the 1st group. After 
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two months of treatment concentration of these 
indicators in patients of the group 1 increased 
significantly due to complications related to the 
ATD in the liver and heart. An opposite trend was 
noticed in patients from the group 2, which was 
associated with i.v. administration of ATD, both 
for TB and drug intoxication.
We have made researches of the drugs phar-
macokinetics depending on method of their ap-
plication. The choice of the examination timing 
was based on the pharmacodynamic properties 
of preparations and character of the MBT growth, 
the need to create high peak concentrations in 
the blood and hence the corresponding values  of 
the BBA for successful treatment of TB patients.
Thus, in the 1st hour of the research, average 
and high BBA values in 100% of the cases among 
the groups were determined. In the 2nd group, the 
high BBA values in the 1st hour of the research 
were significantly higher in comparison with the 
control group (p < 0.05).
 In the 3rd hour after the application of drugs, 
the BBA level was recalculated. It should be not-
ed that although the consolidated figures for the 
mean and high values of BBA in the 1st and 2nd 
groups were observed in 100% of cases, the num-
ber of patients with high BBA level prevailed in 
the 2nd group, where intravenous administration 
of drugs was applied.
In the 6th hour of the research, the data of the 
1st and 2nd groups were characterized by a further 
decrease of the bacteriostatic blood activity and 
its detection at low levels. In the group where 
patients received oral chemotherapy, the high 
BBA levels were not detected in any case. Intra-
venous use of ATD was slightly lower taking into 
consideration the consolidated figures of mean 
and high BBA levels compared to the group where 
ATD was taken orally, but this group was char-
acterized by determination of high BBA levels in 
contrast to the first group where high BBAs were 
not detected (Table 4).
One of the most important criterion for cha-
racterizing the treatment efficacy of patients with 
pulmonary TB is the frequency of abacillation in 
patients (Tables 5, 6). According to the presen-
ted data, the frequency of observed abacillation 
using both microscopic and culture methods 
was significantly more real in the group 2 than 
in the 1st one.
In addition, another important criterion char-
acterizing the treatment effectiveness of patients 
with pulmonary TB is healing of the destructions 
and disappearance of infiltrative changes (Table 7). 
Throughout the period of observation, the healing 
of destructions of lung tissue was recorded more 
often among the patients from the second group 
than in the first one.
Regarding the terms of disappearance of in-
filtrative changes (Table 7), so far all the observed 
groups were consistent with the terms of destruc-
tions healing. The only exceptions are the rare 
cases where infiltration had disappeared before 
the destruction healing occurred, or vice versa, 
Table 4. Bacteriostatic blood activity relative to the strain H37Rv
Hour 
of 
study
Groups of 
patients
The values of bacteriostatic activity of blood
Small
1:2 – 1:4
Medium
1:8 – 1:16
High
1:32 – 1:512
Medium and high
1:8–1:512
n % n % n % n %
1 1 group
n = 46
– – – 31 67.39 p < 0.0001 15 32.61 p < 0.0001 46 100 –
2 group
n = 46
– – 6 13.04 40 86.96 46 100
3 1 group
n = 46
– – – 23 50.00 p = 0.2064 23 50.00 p = 0.2064 46 100 –
2 group
n = 46
– – 17 36.96 29 63.04 46 100
6 1 group
n = 46
(6)
18 39.13 p = 0.5152 28 60.87 p<0.0001 – – – 28 60.87 p = 0.5152
2 group
n = 46
(8)
15 32.61 7 10.87 24 52.17 31 67.39
*The difference between indicators 1 and 2 groups
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Table 6.  Indicators of acid-fast bacilli excretion cessation as evidenced by bacteriologic examination of sputum and 
bronchial washing
Stages of treatment (months)* Group 1 Group 2 p-value
n % n %
2 25 54.35 37 80.43* 0.0066
5 19 41.30 8 17.39* 0.0106
* the p-value is difference between parameters in Groups 1 and 2
Table 7. Indicators of destruction lesion healing and infiltrative change alleviation in pulmonary tissue.
Stages of treatment (months)* Group 1 Group 2 p-value
n % n %
2 18 39.13 29 63.04* 0.0204
4 28 60.87 38 82.61* 0.0192
Total to 6 36 78.26 41 89.13 0.1570
a Index value at each stage is calculated based on previous values 
* the p value is difference between parameters in Groups 1 and 2
when infiltration of the lung continued for some 
time at a time of healing.
Thus, the healing timeframes of destructions 
of patients from the group 2 were significantly 
shorter than those from the group 1. This may 
be related to a more massive concentration of 
i.v. chemotherapy at the beginning of treatment 
followed by penetration of ATD into the abnormal 
focus earlier than at oral application.
The immediate effectiveness of treatment 
would be covered incompletely, if the nature of 
residual changes after completion of the main 
course of antimycobacterial therapy in both 
groups was not assessed.
When using i.v. chemotherapy in patients 
with pulmonary TB, there are less residual changes 
observed: small residual changes at the cavern 
site which were healed, or absence of even min-
imal radiological changes stated in 29 (63.04%) 
patients versus 18 (39.13%) in the group 1 (p = 
0.0158), and large residual changes accordingly 
in 17 (36.96%) and 28 (60.87%) (p = 0.0204).
Discussion
TB is out of control in developing countries 
due to increasing poverty, drug-resistant TB and 
HIV coinfection [1, 2]. The use of tablet forms 
of ATD does not always ensure the patient’s re-
covery. This may have many causes, such as 
comorbidities, the presence of malabsorption 
syndrome and others, which translates to a re-
Table 5.  Indicators of acid-fast bacilli excretion cessation as evidenced by microscopic examination of sputum and bron-
chial washing
Stages of treatment (months) Group 1 Group 2 p-value
n % n %
On admission to hospital 39 84.78 41 89.13 0.5365
1 18 46.15 29 70.73* 0.0238
2 12 30.77 10 24.39 0.5238
3 5 12.82 2 4.88 0.2078
5 4 10.26 0 0 –
* the p-value is difference between parameters in Groups 1 and 2
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duced concentration of ATD in the blood [3, 19]. 
In view of such situation, it is clear that safer and 
better therapies of TB patients are needed. The 
results of this randomized study in a represen-
tative population of TB patients indicates that 
the first line intravenous ATD have produced 
faster clearance of M. tuberculosis and healing 
destruction in the lungs at a significantly higher 
rate than in the control arm. This response rate, 
which occurred within such a  short period of 
time, has rarely been seen in oral chemotherapy 
trials [8, 28].
It is well known that cough, pain in the chest, 
increased body temperature, fever, profuse night 
sweats, fatigue, dyspnea, and loss of weight and 
decreased appetite content are requisite param-
eters to gauge the severity of TB [26–28]. The 
return of these indices to normal is the symptom 
of disease control and a good correlation with 
sputum conversion have been found [5]. Caseous 
pneumonia, tuberculous meningitis, disseminat-
ed and miliary TB are independent risk factors 
associated with poor prognosis; intravenous 
ATD are known to reduce mortality among these 
TB patients [16, 21]. Intravenous ATD helps to 
reduce symptoms of intoxication in a higher pro-
portion of patients, in other words, 61.2 versus 
24.9 % in control group — a ratio that matches 
sputum conversion rate. Consumption is a term 
historically synonymous with TB and represents 
poorly manageable wasting syndrome associated 
with malnutrition and chronic inflammation [29]. 
Finally, as judged by ALT and AST assays, intra-
venous ATD counteract drug-induced hepatotox-
icity — an important factor that affects negatively 
compliance and success of TB chemotherapy.
What is the mechanism of intravenous ATD 
action? In each form of TB, immunopathological 
inflammation caused by the violation of micro-
circulation and trophic factors of lung tissue 
occurs, which may be complicated by its melt-
ing, secreting of caseating masses through the 
bronchi, and the formation of destructions (i.e., 
the process transition in the destructive form). 
This worsens the course of TB, resulting in the 
subsequent loss of a part or even the whole organ. 
All this complicates the penetration of oral ATD 
in the focus of tuberculous inflammation [4, 30]. 
Intravenous chemotherapy increases the concen-
tration of ATD in the blood in a short period of 
time, ensures a rapid access of these drugs to the 
focus of tuberculous inflammation and the use 
of solutions of intravenous ATD provides faster 
detoxication in patients with TB [15, 22]. In ad-
dition, the results of studies during the past years 
have proved that the antimicrobial effect of ATD 
depends only on their maximum concentration in 
the blood, whereas the duration of contact with 
MBT is not significant [10, 25]. We demonstrated 
that intravenous administration of ATD allows 
creating a high level of bacteriostatic blood activ-
ity and maximum concentration in blood serum 
of patients as much as 2.5 times higher compared 
to oral use.
It should be mentioned that the treatment 
of patients with pulmonary TB with the use of 
i.v. chemotherapy accelerates normalization of 
TB clinical aspects and the progress of a specific 
process. No serious adverse events including 
severe allergic and toxic reactions to applied i.v. 
chemotherapy were observed. It was found that 
i.v. chemotherapy has been well tolerated and 
safe. Thanks to i.v. chemotherapy, the terms of 
abacillation and the frequency of destruction 
healing increased together with the frequency of 
achievement of complete clinical and radiological 
cure of patients with a decrease in the number 
of large residual changes after the treatment. In 
addition, due to the use of i.v.  chemotherapy, 
more rapid penetration of drugs into specific 
focus of inflammation has been achieved, full 
bioavailability of drugs and a 100% controllability 
of treatment has been observed.
This treatment effect will help to improve 
further patient’s life after recovery of TB, prevent 
patient from disability due to TB and relapse of 
TB as well as development of drug resistance re-
sistance of MTB [14], which in turn will reduce 
the costs of treatment of TB patients in the future.
Thus, the feasibility of i.v. chemotherapy for 
patients with pulmonary TB has been confirmed.
Conclusions
Thanks to i.v. chemotherapy, in patients with 
pulmonary TB, clinical aspects were eliminated 
faster, severe side effects of ATD have not been 
noticed, time of bacterial clearance and healing 
destruction is reduced, and the healing frequen-
cy of destructions is increased and the residual 
changes have been lessened. 
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